Personalised radionuclide therapy of liver tumours
Injecting 90Y-loaded microspheres into liver tumours by their blood supply is called selective internal radiotherapy (SIRT). SIRT benefits patients because the absorbed radiation dose is better tolerated in the liver than from conventional external beam radiotherapy (EBRT). However, while EBRT dose is prescribed in advance, SIRT dose can only be measured after it has been delivered. To address this limitation, a personalised approach is needed.
Elliot's work aims to personalise SIRT by investigating:
- clinical outcomes based on absorbed dose from SIRT
- the radiobiology of SIRT compared to EBRT
- topping-off undertreated areas from SIRT with EBRT
- emerging noninvasive imaging techniques of blood perfusion to predict SIRT dose
Combining External Beam Radiation and Radionuclide Therapies: Rationale, Radiobiology, Results and Roadblocks.
Abbott EM. et al, (2021), Clin Oncol (R Coll Radiol)
Stereotactic Inverse Dose Planning After Yttrium-90 Selective Internal Radiation Therapy in Hepatocellular Cancer
Abbott E. et al, (2021), Advances in Radiation Oncology, 6
Radiosensitivity of colorectal cancer to 90Y and the radiobiological implications for radioembolisation therapy.
Lee BQ. et al, (2019), Phys Med Biol, 64
Dosimetric Analysis of Individual Liver Metastases from Colorectal Cancer Following 90 y Microsphere Selective Internal Radiation Therapy
Abbott EM. et al, (2017), INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 99, E132 - E132
NTCP calculations for Selective Internal RadioTherapy (SIRT) - demonstration of the methodology
Abbott EM. et al, (2015), EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 42, S330 - S330